Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.46 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774692 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL30785146 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL30662327 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL29774660 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL31484226 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL30807971 | 0.98 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL29777802 | 0.95 | FOLH1 (0.55) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL30335703 | 0.95 | FOLH1 (0.55) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL29898192 | 0.94 | ERAP2 (0.56) | FOLH1ERAP2ERAP1LNPEPCPB2 | |
| SCHEMBL30959072 | 0.93 | FOLH1 (0.53) | FOLH1ERAP2ERAP1LNPEPCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| CN-117120097-A | Selective drug release of internalized bioactive compound conjugates | 思进公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | FOLH1 23/4885ERAP2 62/4885ERAP1 34/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | FOLH1 23/4885ERAP2 62/4885ERAP1 34/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | FOLH1 23/4885ERAP2 62/4885ERAP1 34/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | FOLH1 23/4885ERAP2 62/4885ERAP1 34/4885 |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | FOLH1 23/4885ERAP2 62/4885ERAP1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.